Skye Bioscience (SKYE)

• Market cap: $37.2M
• 1 day: -13.67%
• 5 days: -14.89%
• 1 month: -52.76%
• 3 months: -61.29%
• 6 months: -68.99%
• Year to date: -57.89%
• 1 year: -90.54%
• 5 years: -90.54%
• 10 years: -90.54%
• Sector: Healthcare
• Industry: Biotechnology

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

190% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 10

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

1% less funds holding

Funds holding: 74 [Q3] → 73 (-1) [Q4]

1.76% less ownership

Funds ownership: 84.84% [Q3] → 83.09% (-1.76%) [Q4]

29% less capital invested

Capital invested by funds: $101M [Q3] → $71.3M (-$29.3M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 1,067% upside
• Avg. target: $14.50 1,108% upside
• High target: $15 1,150% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Craig-Hallum Albert Lowe 17% 1-year accuracy 1 / 6 met price target	1,067% upside $14	Buy Maintained	21 Mar 2025
Citizens Capital Markets Jonathan Wolleben 25% 1-year accuracy 18 / 72 met price target	1,150% upside $15	Market Outperform Reiterated	21 Mar 2025